Safety and efficacy of hydroxychloroquine for treatment of non‑severe COVID‑19 among adults in Uganda: a randomized open label phase II clinical trial

Simple item page
dc.contributor.authorByakika‑Kibwika, Pauline
dc.contributor.authorSekaggya‑Wiltshire, Christine
dc.contributor.authorSemakula, Jerome Roy
dc.contributor.authorNakibuuka, Jane
dc.contributor.authorMusaazi, Joseph
dc.contributor.authorKayima, James
dc.contributor.authorSendagire, Cornelius
dc.contributor.authorMeya, David
dc.contributor.authorKirenga, Bruce
dc.contributor.authorNanzigu, Sarah
dc.contributor.authorKwizera, Arthur
dc.contributor.authorNakwagala, Fred
dc.contributor.authorKisuule, Ivan
dc.contributor.authorWayengera, Misaki
dc.contributor.authorMwebesa, Henry G.
dc.contributor.authorKamya, Moses R.
dc.contributor.authorBazeyo, William
dc.date.accessioned2022-01-14T07:44:55Z
dc.date.available2022-01-14T07:44:55Z
dc.date.issued2021
dc.description.abstractSeveral repurposed drugs such as hydroxychloroquine (HCQ) have been investigated for treatment of COVID-19, but none was confirmed to be efficacious. While in vitro studies have demonstrated antiviral properties of HCQ, data from clinical trials were conflicting regarding its benefit for COVID-19 treatment. Drugs that limit viral replication may be beneficial in the earlier course of the disease thus slowing progression to severe and critical illness. Design: We conducted a randomized open label Phase II clinical trial from October–December 2020. Methods: Patients diagnosed with COVID-19 using RT-PCR were included in the study if they were 18 years and above and had a diagnosis of COVID-19 made in the last 3 days. Patients were randomized in blocks, to receive either HCQ 400 mg twice a day for the first day followed by 200 mg twice daily for the next 4 days plus standard of care (SOC) treatment or SOC treatment alone. SARS COV-2 viral load (CT values) from RT-PCR testing of samples collected using nasal/orapharyngeal swabs was performed at baseline, day 2, 4, 6, 8 and 10. The primary outcome was median time from randomization to SARS COV-2 viral clearance by day 6.en_US
dc.identifier.citationByakika-Kibwika, P., Sekaggya-Wiltshire, C., Semakula, J. R., Nakibuuka, J., Musaazi, J., Kayima, J., ... & Bazeyo, W. (2021). Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial. BMC Infectious Diseases, 21(1), 1-11. https://doi.org/10.1186/s12879-021-06897-9en_US
dc.identifier.urihttps://doi.org/10.1186/s12879-021-06897-9
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1275
dc.language.isoenen_US
dc.publisherBMC Infectious Diseasesen_US
dc.subjectCOVID-19en_US
dc.subjectHydroxychloroquineen_US
dc.subjectOutcomesen_US
dc.subjectTreatmenten_US
dc.subjectSafetyen_US
dc.subjectEfficacyen_US
dc.titleSafety and efficacy of hydroxychloroquine for treatment of non‑severe COVID‑19 among adults in Uganda: a randomized open label phase II clinical trialen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Safety and efcacy of hydroxychloroquine rs.pdf
Size:
760.76 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences